Share This Article:

The Effect of Antiretroviral Therapy (ART) on Body Composition and Clinical Markers of Lipodystrophy in HIV-Infected Children Assessed in Follow-Up Study

Abstract Full-Text HTML Download Download as PDF (Size:95KB) PP. 252-258
DOI: 10.4236/wja.2012.23033    3,661 Downloads   5,569 Views  

ABSTRACT

Objectives: Antiretroviral therapy (ART) has been associated with lipodystrophy in children. We evaluated changes in various anthropometric measurements for the assessment of lipodystrophy and assessed whether there was an association with use of protease inhibitors (PI), non-PI containing ART and/or stavudine (d4T). Methods: Eighty-five HIV-infected children attending the HIV clinic at Great Ormond Street Hospital (GOSH) were included. The average follow-up was 8.4 months (range 3 - 12 months). Body fat redistribution was assessed by anthropometric measurements including skinfold thickness and circumferences of upper and lower limbs. Measurements were converted to age- and sex-adjusted z-scores through development stages including puberty. Results: Sixty children had taken ART; 37 received PI-containing; 38 received d4T; 25 had never been treated. In the studied population, clinically important changes with decreases in biceps (BSF), subscapular skinfolds and total body fat (4SFT) over period of 12 months were observed. Some increase was noticed in triceps skinfolds (TSF). Limbs circumferences remained at the same level. Further we looked at 4 months basis changes in anthropometric measurements stratified by baseline ART. Generally z-scores of anthropometric measurements were lower in therapy naive children when compared to ART groups. PI-based ART regimens resulted in significant increases in BSF with a trend towards increases in TSF, suprailiac and 4SFT. Mid-arm and thigh circumferences were higher in PI compared to naive group. Similarly, significant changes in BSF z-scores were associated with d4T use. Increases were seen in TSF and mid-arm circumference and decreases were observed in subscapular skinfolds and calf circumference z-scores. Conclusions: Body fat redistribution in HIV-infected children with sub-clinical lipodystrophy could be detected by anthropometric measurements, particularly when PI or d4T is included in ART. Over time, changes with increase in arm and trunk fat, and no change or decrease in leg fat were more pronounced among ART-receiving children.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

A. B. Dzwonek, V. Novelli, C. Smith and M. Lawson, "The Effect of Antiretroviral Therapy (ART) on Body Composition and Clinical Markers of Lipodystrophy in HIV-Infected Children Assessed in Follow-Up Study," World Journal of AIDS, Vol. 2 No. 3, 2012, pp. 252-258. doi: 10.4236/wja.2012.23033.

References

[1] D. M. Gibb, T. Duong, P. A. Tookey, M. Sharland, G. Tudor-Williams, V. Novelli, et al., “Decline in Mortality, AIDS, and Hospital Admissions in Perinatally HIV-1 Infected Children in the United Kingdom and Ireland,” BMJ, Vol. 327, No. 7422, 2003, pp. 1019-1023. doi:10.1136/bmj.327.7422.1019
[2] D. Jaquet, M. Levine, E. Ortega-Rodriguez, A. Faye, M. Polak, E. Vilmer, et al., “Clinical and Metabolic Presentation of the Lipodystrophic Syndrome in HIV-Infected Children,” AIDS, Vol. 14, 2000, pp. 2123-2128. doi:10.1097/00002030-200009290-00008
[3] S. M. Arpadi, P. A. Cuff, M. Horlick, J. Wang, D. P. Kotler, “Lipodystrophy in HIV-Infected Children is Associated with High Viral Load and Low CD4+-Lymphocyte Count and CD4+-Lymphocyte Percentage at Baseline and Use of Protease Inhibitors and Stavudine,” Journal of Acquired Immune Deficiency Syndromes, Vol. 27, No. 1, 2001, pp. 30-34.
[4] R. A. Amaya, C. A. Kozinetz, A. McMeans, H. Schwarzwald and M. W. Kline, “Lipodystrophy Syndrome in Human Immunodeficiency Virus-Infected Children,” The Pediatric Infectious Disease Journal, Vol. 21, No. 5, 2002, pp. 405-410. doi:10.1097/00006454-200205000-00011
[5] A. Vigano, S. Mora, C. Testolin, S. Beccio, L. Schneider, D. Bricalli, et al., “Increased Lipodystrophy Is Associated with Increased Exposure to Highly Active Antiretroviral Therapy in HIV-Infected Children,” Journal of Acquired Immune Deficiency Syndromes, Vol. 32, No. 5, 2003, pp. 482-489. doi:10.1097/00126334-200304150-00003
[6] European Paediatric Lipodystrophy Group, “Antiretroviral Therapy, Fat Redistribution and Hyperlipidaemia in HIV-Infected Children in Europe,” AIDS, Vol. 18, No. 10, 2004, pp. 1443-1451. doi:10.1097/01.aids.0000131334.38172.01
[7] E. G. Leonard and G. A. McComsey, “Metabolic Complications of Antiretroviral Therapy in Children,” Pediatric Infectious Diseases Journal, Vol. 22, No. 1, 2003, pp. 77-84. doi:10.1097/00006454-200301000-00018
[8] N. Alam, M. Cortina-Borja, T. Goetghebuer, M. Marczynska, A. Vigano and C. Thorne, “For the European Paediatric HIV and Lipodystrophy Study Group in EuroCord; Body Fat Abnormality in HIV-Infected Children and Adolescents Living in Europe: Prevalence and Risk Factors,” Journal of Acquired Immune Deficiency Syndromes, Vol. 59, No. 3, 2012, pp. 314-324. doi:10.1097/QAI.0b013e31824330cb
[9] A. B. Dzwonek, M. S. Lawson, T. J. Cole and V. Novelli, “Body Fat Changes and Lipodystrophy in HIV-Infected Children: Impact of Highly Active Antiretroviral Therapy,” Journal of Acquired Immune Deficiency Syndromes, Vol. 43, No. 1, 2006, pp. 121-123. doi:10.1097/01.qai.0000230523.94588.85
[10] M. Beregszaszi, C. Dollfus, M. Levine, A. Faye, S. Deghmoun, N. Bellal, et al., “Longitudinal Evaluation and Risk Factors of lipodystrophy and Associated Metabolic Changes in HIV-Infected Children,” Journal of Acquired Immune Deficiency Syndromes, Vol. 40, No. 2, 2005, pp. 161-168. doi:10.1097/01.qai.0000178930.93033.f2
[11] S. M. Arpadi, J. Bethel, M. Horlick, M. Sarr, M. Bamji, E. J. Abrams, et al., “Longitudinal Changes in Regional Fat Content in HIV-Infected Children and Adolescents,” AIDS, Vol. 23, No. 12, 2009, pp. 1501-1509. doi:10.1097/QAD.0b013e32832b7e69
[12] P. Taylor, C. Worrell, S. M. Steinberg, R. Hazra, S. Jankelevich, L. V. Wood, et al., “Natural History of Lipid Abnormalities and Fat Redistribution among Human Im- munodeficiency Virus-Infected Children Receiving Long-Term, Protease Inhibitor-Containing, Highly Active Antiretroviral Therapy Regimens,” Pediatrics, Vol. 114, No. 2, 2004, pp. 235-242. doi:10.1542/peds.114.2.e235
[13] M. Sharland, S. Blanche, G. Castelli, J. Ramos and D. M. Gibb, “PENTA Guidelines for the Use of Antiretroviral Therapy, 2004,” HIV Medicine, Vol. 5, Suppl. 2, 2004, pp. 61-86. doi:10.1111/j.1468-1293.2004.00227.x
[14] W. J. Gerver and R. Bruin, “ Paediatric Morphometrics. A Reference Manual,” 2nd Edition, Universitaire Pers Maastricht, Maastricht, 2001.
[15] A. A. Florindo, R. Latorre Mdo, E. C. Santos, A. Borelli, S. R. Mde and A. A. Segurado, “Validation of Methods for Estimating HIV/AIDS Patients’ Body Fat,” Revista de Saude Publica, Vol. 38, No. 5, 2004, pp. 643-649. doi:10.1590/S0034-89102004000500005
[16] R. Singhania and D. P. Kotler, “Lipodystrophy in HIV Patients: Its Challenges and Management Approaches,” HIV AIDS (Auckland, NZ), Vol. 3, 2011, pp. 135-143.

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.